Kornimate/medical-research-clean huggingface dataset:
vaccination coverage amongst children/young people attending the ped

Conditions: Vaccination/Immunisation Status

Summary: in the united kingdom (uk), most childhood vaccinations are given in the community, although uptake has decreased in recent years. a paediatric emergency department (ped) attendance offers an opportunity to check the vaccination status of children and young people (cyp) and all parents/carers should be asked about this routinely. those not up-to-date with vaccinations could then be signposted to existing services or perhaps offered a vaccine in the ped. cyp attending the ped may also have lower vaccination coverage than their peers, so may benefit even more from interventions to increase uptake. however, recall by parents/carers is not always sufficiently accurate to identify those who have not yet received all their age-appropriate vaccinations. the most complete record of an individual's vaccination history is held within their primary care records. however, these records are often in a separate computer system that is inaccessible from the hospital's main computer system, although some information (including vaccination) may be accessed from within the hospital via a third system. this study aims to see if cyp attending the ped are under-vaccinated compared to their peers and assess the accuracy of parent/carer recall. the results of this study will then be used to inform recommendations for developing better ways to access accurate vaccination data during a ped consultation. if such a system existed, under-vaccinated children could be identified routinely during an attendance, and an intervention offered if appropriate. this would be particularly useful if there was an outbreak of a vaccine-preventable disease such measles. all cyp (\< 16 years old) attending a ped in a district general hospital in manchester will be invited to participate. cyp/their parent/carer will be asked to provide consent for their vaccination records to be accessed as well as being asked if the child/young person is up-to-date with all their vaccinations. approximately 1000 participants will be enrolled.


Eligibility criteria:
inclusion criteria: * attending the study site ped; under the age of 16 at the time of attendance; able to give consent or accompanied by someone able to give consent exclusion criteria: * life threatening illness or injury

Keywords: vaccination immunisation opportunistic child young person paediatric emergency department
classification-directed treatment of low back pain

Conditions: Low Back Pain

Summary: the primary purpose of this proposal is to conduct a prospective, randomized, controlled clinical trial to examine whether or not treatment based on a person's direction-specific, impairment-based lbp classification is more effective than non-specific treatment in improving short- (6 weeks) and long-term (6 and 12 months) outcomes in people with chronic lbp. we hypothesize that treatment based on a person's direction-specific, impairment-based lbp classification (classification-specific) will result in better outcomes than non-specific treatment. our approach to classification-directed treatment is based on the proposal that a person's lbp is the result of adopting direction-specific strategies of movement and alignment of the spine which then are used repeatedly during the person's everyday activities. the exposure of spine tissue to repeated loading in the same direction across a day is proposed to accelerate the accumulation of stress, microtrauma, and eventually lbp. we also hypothesize that until the factors contributing to the use of the direction-specific strategies of the spine are modified, the lbp problem will persist or recur. identification of homogeneous subgroups of people with lbp will enhance 1) the power of clinical trials, 2) prognosis, and 3) the ability to identify mechanisms contributing to different lbp problems.


Eligibility criteria:
inclusion criteria: * people who report a history of chronic lbp for a minimum of 12 months,currently are experiencing lbp symptoms but not in an acute recurrence, * between 18 and 60 years of age, * able to stand and walk without assistance, * able to understand and read english, * able to understand and sign a consent form exclusion criteria: * any structural spinal deformity including scoliosis, kyphosis, or stenosis, * a spinal fracture or dislocation, * osteoporosis, * ankylosing spondylitis, * rheumatoid arthritis, * disc herniation, * serious spinal complications such as tumor or infection, * previous spinal surgery, * frank neurological loss, i.e., weakness and sensory loss, * pain or paresthesia below the knee, * etiology of lbp other than the lumbar spine, e.g., hip joint, * history of neurologic disease which required hospitalization, * active treatment for cancer, * history of unresolved cancer, * pregnancy, * magnified symptom behavior, * worker's compensation or disability case, * in litigation for the lbp problem, * referral from a specialized pain clinic source, * spondylolisthesis

Keywords: low back pain classification spine
shuntcheck accuracy in detecting shunt obstruction normal pressure hydrocephalus (nph) patients

Conditions: Normal Pressure Hydrocephalus

Summary: the purpose of this study is to examine the role of shuntcheck and mr imaging in evaluating the presence or absence of shunt obstruction in the patients of hydrocephalus or idiopathic intracranial hypertension (iih) undergoing radionuclide test for suspected shunt obstruction. this is an exploratory study to determine how a non-invasive device can assist in detection of presence of flow in these patients.

this study aims to correlate findings of shuntcheck and mri with the radionuclide patency study. patients will be enrolled if they have hydrocephalus or iih, present with symptoms of shunt obstruction and will need to undergo shunt patency test and an mri along with standard of care radionuclide study. the shuntcheck study will be conducted in a clinic, doctor's office or in an emergency room by the treating physician or by trained health care professionals. also, patients who are found with shunt obstruction as diagnosed by radionuclide study will undergo shunt revision and the findings of the study will be correlated with operative findings. post shunt replacement patients who also receive adjustable valve will be evaluated with shunt check, before and after adjustment of valves to detect changes in flow as detected by shunt check. this is an exploratory study to determine how a non-invasive device can assist in detection of presence of flow in these patients. approximately 20 subjects will be enrolled in a single site in this proof of concept, physician sponsored study. an approved, commercial device will be available to the site prior to start of the study.

Eligibility criteria:
inclusion criteria: 1. adult patients \> 35 years capable and willing to consent for their participation or consent obtained from a legal guardian. 2. patients with an indwelling shunt and clinical assessment strongly suggestive of shunt obstruction 3. patients are candidates for shunt patency procedures in the elective extension exclusion criteria: 1. patients \<35 years of age 2. patients with symptoms attributable to valve malfunction or shunt infection 3. patients who need urgent shunt replacement and therefore cannot wait for the shuntcheck evaluation of shunt patency. 4. patients with edema or wound of skin overlying the shunt tissue. 5. patients not capable or not willing to consent to participate in the study

Keywords: normal pressure hydrocephalus valve adjustment blocked shunt in nph patients diagnosis of blockage
a non-interventional pilot study to explore the role of gut flora in obesity

Conditions: Overweight and Obesity; Overweight or Obesity; Obesity; Obesity, Morbid; Obesity, Abdominal; Obesity; Familial; Obesity; Endocrine; Obesity, Visceral; Obesity Hypoventilation Syndrome

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding obesity.

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records, particularly regarding obesity.

Eligibility criteria:
inclusion criteria: 1. signed informed consent by patient 2. male or female patients age 18 and older. 3. diagnosis of obesity based on body mass index (bmi) of 30 or greater. exclusion criteria: 1. refusal by patient to sign informed consent form 2. treatment with antibiotics within two weeks prior to screening 3. treatment with probiotics within six weeks prior to screening 4. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy 5. postoperative stoma, ostomy, or ileoanal pouch 6. participation in any experimental drug protocol within the past 12 weeks 7. treatment with total parenteral nutrition 8. any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial 9. inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study
epidemiology, management, prognosis and medical cost analysis of ihca and ohca

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the study is a retrospective analysis of taiwan national health insurance in cardiac arrest patients. the factors related to the outcomes of cardiac arrest patients were analyzed.


Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest, exclusion criteria: -
validation imu and emg algorithms in stroke patients

Conditions: Stroke

Summary: the objective is to validate the algorithms for movement analysis that were developed previously in healthy participants, in a small study with stroke patients. stroke subjects will be measured while performing tasks like walking, sitting and standing while wearing light-weight inertial measurements units (imus) incorporating 3d accelerometers, 3d gyroscopes and surface electromyography. during the measurements subjects will be recorded on video that serves as ground truth when validating the implemented algorithms for movement analysis. a face blurring program will be used for all video footage.

subjects will perform the following tasks: 30 sec stationary sitting/standing/lying; 10m walk test; l-test; 8-figure walking test; daily life task; stepping over small obstacles; walk in the corridor. during the measurments imu will be placed at: sternum; sacrum; bilateral wrists; bilateral shanks; bilateral upper legs; both feet. surface emg of bilateral rectus femoris; vastus lateralis; medial gastrocnemius and soleus will be measured.

Eligibility criteria:
inclusion criteria: * min 18 yrs of age; history of previous stroke; unilateral affected;able to walk without supervision (fac-score min 4);able to perform activities of daily living without assistance (self-reported); written informed consent. exclusion criteria: * subjects with neurological or motor disorders that could interfere with the measurements (other than stroke) or severe deficits in communication, memory and understanding.
kinesiophobia and physical fitness, and related factors in liver transplantation

Conditions: Liver Transplant Disorder

Summary: kinesiophobia and physical fitness, and related factors in liver transplantation


Eligibility criteria:
inclusion criteria: * all patients older than 18 years of age who had undergone liver transplantation at hacettepe university hospital at least one year ago were eligible for the study. exclusion criteria: * hepatic encephalopathy * progressive cardiac and/or pulmonary disease * central nervous system pathologies * orthopedic problems preventing physical assessments * multiorgan transplantation * cognitive deficits

Keywords: liver transplantation functional capacity kinesiophobia balance physical fitness physical activity muscle strength
a study to learn about the investigational medicine called pf-06821497 (mevrometostat) in men with mcrpc who were previously treated with abiraterone acetate for prostate cancer (mevpro-1).

Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Summary: pfizer mevpro-1 (c2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (pf-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (ar) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mcrpc) after progression on prior abiraterone acetate treatment. the primary objective of this clinical trial is to assess the radiographic progression free survival (rpfs) of the combination of pf-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * metastatic disease in bone documented on bone scan, or in soft tissue documented on ct/mri scan. * progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mcspc setting or first line mcrpc setting is required. * eastern cooperate oncology group (ecog) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator. exclusion criteria: * any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study. * know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery. * clinically significant cardiovascular disease. * known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure. * prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177lu-psma-617, radium 223), androgen receptor signaling inhibitors (arsi) including enzalutamide, apalutamide, darolutamide, poly adp-ribose polymerase (parp) monotherapy or other systemic anti-cancer treatment, with the following exceptions: 1. treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention. 2. docetaxel treatment is allowed for mcspc, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion. * previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter). * inadequate organ function.

Keywords: prostate cancer enhancer of zeste homolog 2 castrate resistant prostate cancer hormone resistant metastatic hormone resistant prostate cancer metastatic castrate resistant prostate cancer pf-06821497 enzalutamide docetaxel advanced prostate cancer efficacy safety open-label relapsed refractory
bevacizumab + paclitaxel + capecitabine in triple negative metastatic breast cancer

Conditions: Triple Negative Metastatic Breast Cancer

Summary: patients with triple negative metastatic breast cancer (her2-, pr-, er-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).


Eligibility criteria:
inclusion criteria: * female histologically confirmed adenocarcinoma of the breast er-, pr-, her2- disease * measurable disease * patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry exclusion criteria: * prior chemotherapy for metastatic disease * her2 positive and/or hormonal receptor positive

Keywords: triple negative metastatic breast cancer first line chemotherapy
directly observed therapy for community-released hiv+ prisoners

Conditions: HIV/AIDS; Substance Abuse

Summary: the aim of this study is to develop effective interventions for hiv-infected prisoners who are released to the community. the intervention that we will study will be directly observed therapy (daart/dot) and we will compare this to the current standard of care that involves self-administered therapy (sat). all subjects will get transitional case management and all subjects with a prior history of opiate dependence will be offered opiate substitution therapy (buprenorphine or methadone). hypotheses: * at the end of six months those receiving daart will have a higher level of adherence to haart as compared to the sat group. * the daart intervention will result in subjects having lower viral loads and higher cd4 counts as compared to the sat group. * at the end of six months, the daart group will have a lower rate of recidivism to jail/prison as compared to the sat group. * over the year, the daart group will be more likely to make repeated primary hiv care visits than the sat group.

any individual that is hiv positive and incarcerated for at least a period of 90 days and on antiretroviral medications would be referred to the study by the medical staff of the incarceration facilities prior to release or within 30 days of release an individual would be able to self refer. subjects would be screened and consented and interviewed prior to their release from incarceration, on their day of release, and monthly for a period of one year. at the time of their day of release interview, subjects are randomized to either the intervention daart group or the standard of care sat group. all subjects would be assessed and offered opiate substitution therapy if there was a prior history of opiate dependency as a means of relapse prevention. subjects in daart would be seen everyday for a period of six months by a team of research assistants who observe the subjects taking their medications, and their last six months would be done as standard of care. standard of care sat subjects would continue to take their medications on their own as prescribed. all subjects would be interviewed monthly and quarterly would have laboratory blood tests completed.

Eligibility criteria:
inclusion criteria: * hiv seropositive * 18 years of age or older * incarcerated for a minimum of 90days * living in new haven or hartford * currently on haart or willing to begin haart medications exclusion criteria: * not meeting inclusion criteria

Keywords: hiv aids substance abuse directly administered antiretroviral therapy adherence substance abuse and dependency
trigger point injections in anterior cervical surgery

Conditions: Myofacial Pain; Pain, Neck; Pain, Back; Cervical Fusion

Summary: to achieve appropriate exposure for an anterior neck surgery (for example an anterior cervical discectomy and fusion or acdf), patients are positioned supine with their neck extended. due to being in this position, patients frequently complain of posterior neck stiffness and pain postoperatively in addition to the anterior incisional pain. this posterior cervical pain can be classified as myofascial pain. cervical myofascial pain is thought to be the result of overuse or trauma to the supporting muscles of the neck and shoulders. trigger point injections are one of the methods used to treat myofascial pain. the trigger point injection procedure is where a physician (typically an anesthesiologist) performs an exam of the patient neck and upper back and finds areas of point tenderness. the physician will then inject a small amount of numbing medication (such as bupivacaine) into the muscle or tissue in that area. trigger point injections have been shown to be superior to botox injections or dry needling, and equivalent to physical therapy. however, these studies were performed on patients with chronic neck pain. there are no studies evaluating the effectiveness of trigger point injections on post anterior cervical surgery patients. at our institution, trigger point injections with local anesthetic are used as part of a multimodal pain control regimen for post-anterior cervical surgery patients. our hypothesis is if the addition of trigger point injections to standard of care multi-modal post-operative pain control will decrease patients' myofascial pain, and thereby decrease the amount of narcotic pain medication used.


Eligibility criteria:
inclusion criteria: * elective anterior cervical surgery exclusion criteria: * emergency surgery * local anesthetic allergy * long term opioid usage (not including tramadol and codeine) * intra-operative complication (e.g. unstable cervical spine)
caffeinated chewing gum on 400-meter performance

Conditions: Caffeine; Placebo

Summary: 20 trained sprinter were divided into caffeine gum trial (caf) and placebo trial (pl) with a randomized, double-blind study design. the participants chewing either caffeine gum (caf trial, containing 3 mg/kg of caffeine) or placebo gum (pl) for 10 minutes. the outcomes are running-based anaerobic sprint test and 400-meter sprint test was performed.

the purpose of this study was to investigate the effect of caffeinated chewing gum on 400-meter sprint performance. 20 trained sprinter were divided into caffeine gum trial (caf) and placebo trial (pl) with a randomized, double-blind study design. the participants chewing either caffeine gum (caf trial, containing 3 mg/kg of caffeine) or placebo gum (pl) for 10 minutes. after rested for 15 minutes, the participants underwent a running-based anaerobic sprint test. after a 30-minute break, a 400-meter sprint test was performed. the blood lactate concentration were collected before and after 400-meter sprint from finger. saliva samples were predicted to be collected before chewing gum, before the rast, and after a 400-meter sprint. saliva samples will be analyzed for caffeine and α-amylase concentrations in saliva.

Eligibility criteria:
inclusion criteria: * 6 years of professional short sprinting training * 6 months of ongoing training, and * 3 months of recovery from sports injuries such as strains and sprains. exclusion criteria: * non-specialized sprinters. * has not trained regularly for the past 6 months. * has recovered from an athletic injury. * less than 3 months of recovery from a sports injury, or participants with epilepsy, hypertension, hyperlipidemia, heart disease, arthritis, osteoporosis, brain injury, or a history of caffeine allergy.

Keywords: exercise performance fatigue index α amylase
nettunit - italy-tunisia cross-border environmental network_2

Conditions: Risk Perception

Summary: the study involves the development and validation of a questionnaire for risk perception to be administered to residents of areas declared to be at high risk of environmental crisis in the areas of caltanissetta (italy) and tunis (tunisia). the questionnaire will be administered twice, at baseline and after 1 month.


Eligibility criteria:
inclusion criteria: * individuals aged 20-90 years of both sex, living in the areas of caltanissetta (italy) and tunis (tunisia). exclusion criteria: * individuals with learning difficulties.